Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
International Immunopharmacology|September 24, 2016
Immunosuppressive effect of ASP2408, a novel CD86-selective variant of CTLA4-Ig, in rats and cynomolgus monkeysShinsuke Oshima, Yasutomo Fujii, Erik E Karrer, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 1995
In situ isolation of mRNA from individual plant cells: creation of cell-specific cDNA librariesE E Karrer, J E Lincoln, S Hogenhout, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 24, 2015
A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantationD J Lo, D J Anderson, M Song, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate TherapyWenhui Zhang, Robert M Kernstock, Erik E Karrer, et al.
Transplantation|November 19, 2016
The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman PrimatesShinsuke Oshima, Erik E Karrer, Yuka Kawato, et al.
Clinical Pharmacology in Drug Development|July 14, 2016
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA PatientsTong Zhu, James Keirns, Corrie Howieson, et al.
Protein Engineering, Design & Selection : PEDS|March 13, 2016
ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolutionShinsuke Oshima, Erik E Karrer, Madan M Paidhungat, et al.
Pageof 2